Company: LGNZZ
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0000886163-25-000063
Chunk: 9

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-11-07
Form: 10-Q
Item: Item 1
Chunk 9
---
 from issuance of 2030 Convertible Senior Notes460,000 —    Debt discount and payment of debt issuance cost(14,911)(308)   Purchase of 2030 Convertible Senior Notes hedge(113,250)—    Proceeds from issuance of warrants67,390 —    Repurchase of common stock(15,000)—    Proceeds from common stock issuance, net of commissions and fees— 34,030    Payments under finance lease obligations(20)(19)   Payments to CVR holders(174)—    Net proceeds from stock option exercises and ESPP38,203 46,251    Taxes paid related to net share settlement of equity awards(9,255)(3,201)   Proceeds from Pelthos investors6,910 — Net cash provided by financing activities419,893 76,753 Effect of exchange rate changes on cash and cash equivalents2,950 377 Net increase in cash and cash equivalents67,069 40,665 Cash and cash equivalents at beginning of period72,307 22,954 Cash and cash equivalents at end of period$139,376 $63,619 

Supplemental disclosure of cash flow information:   Interest paid$299 $262    Taxes paid$5,175 $17,346    Apeiron Acquisition:      Fair value of tangible assets acquired, net of cash and restricted cash received$— $8,965       Financial royalty assets— 106,156       Liabilities assumed— (23,125)   Cash paid for Apeiron Acquisition, net of cash received$— $91,996 Supplemental schedule of non-cash investing and financing activities:   Pelthos shares received in exchange for LNHC, Inc. business$44,092 $—    Pelthos shares received for a bridge loan cancellation$12,732 $—    Addition of right-of-use assets and lease liabilities$2,315 $1,769    Accrued debt issuance costs$634 $8    Accrued fixed asset purchases$— $289    Unrealized gain on available-for-sale investments, net of tax$7 $3 

See accompanying notes to unaudited condensed consolidated financial statements.

10

LIGAND PHARMACEUTICALS INCORPORATED